Ironwood Puts It Bluntly: Denner Lacks Case To Join Board, Wouldn’t Provide Missing Insight
Executive Summary
Citing concerns that Linzess might not hit the blockbuster threshold by 2020, as predicted by Ironwood, one analyst lowers the firm’s stock rating on the same day the company clarifies that it does not want activist investor Alex Denner to join its board.
You may also be interested in...
Cyclerion Readies For Readouts In Sickle Cell, Other Rare, Serious Diseases This Year
Spun out from Ironwood with a $175m financing, Cyclerion added Bayer and Shire veteran Andreas Busch to its management team as Chief Innovation Officer as it awaits a trio of Phase II data readouts coming this year for its sGC stimulators.
Ironwood Being Split In Two: Is Move To Thwart Activist Investor Sarissa?
Move will spin out sGC assets into solo listed group while smaller Ironwood will focus on GI diseases and abdominal pain.
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.